IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v14y2016i4d10.1007_s40258-016-0248-z.html
   My bibliography  Save this article

A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence

Author

Listed:
  • Philippe Laramée

    (Centre for Addiction and Mental Health)

  • Aurélie Millier

    (Creativ-Ceutical)

  • Nora Rahhali

    (Lundbeck SAS)

  • Olivier Cristeau

    (Creativ-Ceutical)

  • Samuel Aballéa

    (Creativ-Ceutical)

  • Clément François

    (Lundbeck SAS)

  • Ylana Chalem

    (Lundbeck SAS)

  • Mondher Toumi

    (Université de la Méditerranée)

  • Jürgen Rehm

    (Centre for Addiction and Mental Health
    University of Toronto
    TU Dresden)

Abstract

Background Alcohol dependence causes considerable harm to patients. Treatment with nalmefene, aiming to reduce consumption rather than maintain complete abstinence, has been licensed based on trials demonstrating a reduction in total alcohol consumption and heavy drinking days. Relating these trial outcomes to harmful events avoided is important to demonstrate the clinical relevance of nalmefene treatment. Methods A predictive microsimulation model was developed to compare nalmefene plus brief psychosocial intervention (BRENDA) versus placebo plus BRENDA for the treatment of patients with alcohol dependence and a high or very high drinking risk level based on three pooled clinical trials. The model simulated patterns and level of alcohol consumption, day-by-day, for 12 months, to estimate the occurrence of alcohol-attributable diseases, injuries and deaths; assessing the clinical relevance of reducing alcohol consumption with treatment. Results The microsimulation model predicted that, in a cohort of 100,000 patients, 971 (95 % confidence interval [CI] 904–1038) alcohol-attributable diseases and injuries and 133 (95 % CI 117–150) deaths would be avoided with nalmefene versus placebo. This level of benefit has been considered clinically relevant by the European Medicines Agency. Conclusions This microsimulation model supports the clinical relevance of the reduction in alcohol consumption, and has estimated the extent of the public health benefit of treatment with nalmefene in patients with alcohol dependence and a high or very high drinking risk level.

Suggested Citation

  • Philippe Laramée & Aurélie Millier & Nora Rahhali & Olivier Cristeau & Samuel Aballéa & Clément François & Ylana Chalem & Mondher Toumi & Jürgen Rehm, 2016. "A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 493-505, August.
    • Handle: RePEc:spr:aphecp:v:14:y:2016:i:4:d:10.1007_s40258-016-0248-z
    DOI: 10.1007/s40258-016-0248-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-016-0248-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-016-0248-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Salah Ghabri & Françoise F. Hamers & Jean Michel Josselin, 2016. "Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health," PharmacoEconomics, Springer, vol. 34(6), pages 617-624, June.
    2. Jonathan Karnon & James Stahl & Alan Brennan & J. Jaime Caro & Javier Mar & Jörgen Möller, 2012. "Modeling Using Discrete Event Simulation," Medical Decision Making, , vol. 32(5), pages 701-711, September.
    3. V. J. Roelofs & M. C. Kennedy, 2011. "Sensitivity Analysis and Estimation of Extreme Tail Behavior in Two‐Dimensional Monte Carlo Simulation," Risk Analysis, John Wiley & Sons, vol. 31(10), pages 1597-1609, October.
    4. Oakley, Jeremy E. & Brennan, Alan & Tappenden, Paul & Chilcott, Jim, 2010. "Simulation sample sizes for Monte Carlo partial EVPI calculations," Journal of Health Economics, Elsevier, vol. 29(3), pages 468-477, May.
    5. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.
    6. Joke Bilcke & Philippe Beutels & Marc Brisson & Mark Jit, 2011. "Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models," Medical Decision Making, , vol. 31(4), pages 675-692, July.
    7. Oluwatomi Adetunji & John Bischoff & Christopher J. Willy, 2018. "Managing system obsolescence via multicriteria decision making," Systems Engineering, John Wiley & Sons, vol. 21(4), pages 307-321, July.
    8. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    9. Jonah Popp & John A. Nyman & Xianghua Luo & Jill Bengtson & Katherine Lust & Lawrence An & Jasjit S. Ahluwalia & Janet L. Thomas, 2018. "Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1319-1333, December.
    10. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    11. Jagpreet Chhatwal & Tianhua He, 2015. "Economic Evaluations with Agent-Based Modelling: An Introduction," PharmacoEconomics, Springer, vol. 33(5), pages 423-433, May.
    12. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:14:y:2016:i:4:d:10.1007_s40258-016-0248-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.